Nilai Buku saben Saham: Puma Biotechnology Inc (PBYI)

Puma Biotechnology is expanding the global distribution of its oncology products through licensing agreements with foreign pharmaceutical giants. The company is enhancing the efficiency of data analysis in clinical trials using AI platforms, eliminating manual documentation collection. The current metric stands at 2.69. The price trend complements a picture of moderate scientific activity focused on expanding the application of Nerlynx and studying kinase inhibitors.

For Puma Biotechnology (PBYI), which focuses on monetizing a single oncology drug, this indicator determines the real value of a shareholder's stake through the ratio of net assets to the number of shares. By analyzing the book value per share under IFRS, an investor verifies the business's intrinsic capitalization, which is critical in the absence of a merger strategy and given the dependence on distribution licensing rights.